NRX Pharmaceuticals CFO gets 75,000-unit stock grant

The three annual vesting installments are each subject to continued service through the applicable vesting date.

Available on EDGAR 11/04/2026 - 05:52 PM EST Accepted by SEC EDGAR 11/04/2026 - 05:52 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

NRX Pharmaceuticals, Inc. (NRXP) Chief Financial Officer Michael S. Abrams was granted 75,000 restricted stock units on July 28, 2026. Each unit represents a contingent right to receive one common share at vesting for no consideration. The units vest in three equal annual installments on July 28, 2027, July 28, 2028, and July 28, 2029, subject to continued service through each vesting date.

Insider Trade Summary

Grant/Award: 75,000 shares

Grant/Award 1 txn

Insider ABRAMS MICHAEL S

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit F1, F2	75,000	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 75,000 contracts (Direct)

Footnotes (2)

1. F1. Each restricted stock unit ("RSUs') represents a contingent right to receive one share of the Issuer's common stock at the time of vesting for no consideration.
2. F2. The restricted stock units were granted under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan, as amended. The RSUs vest in three equal annual installments on July 28, 2027, July 28, 2028 and July 28, 2029, subject to the reporting person's continued service through each vesting date.

Key Figures

Restricted stock units granted: 75,000 RSUs Vesting installments: 3 equal annual installments First vesting date: July 28, 2027 +2 more

5 metrics

Restricted stock units granted 75,000 RSUs Granted July 28, 2026

Vesting installments 3 equal annual installments Subject to continued service through each vesting date

First vesting date July 28, 2027 RSU vesting schedule

Second vesting date July 28, 2028 RSU vesting schedule

Third vesting date July 28, 2029 RSU vesting schedule

Key Terms

Restricted Stock Unit, 2021 Omnibus Incentive Plan, vesting

3 terms

Restricted Stock Unit financial

"Each restricted stock unit ("RSUs') represents a contingent right"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

2021 Omnibus Incentive Plan financial

"granted under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan"

vesting financial

"at the time of vesting for no consideration"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RSUs did NRXP CFO Michael S. Abrams receive?

NRX Pharmaceuticals Chief Financial Officer Michael S. Abrams was granted 75,000 restricted stock units on July 28, 2026. Each unit represents a contingent right to receive one common share at vesting for no consideration.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ABRAMS MICHAEL S

(Last) (First) (Middle)

C/O NRX PHARMACEUTICALS, INC.

1201 ORANGE STREET, SUITE 600

(Street)

WILMINGTON DELAWARE 19801

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NRX Pharmaceuticals, Inc. [ NRXP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	07/28/2026		A		75,000		(2)	(2)	Common Stock	75,000	$0	75,000	D

Explanation of Responses:

1. Each restricted stock unit ("RSUs') represents a contingent right to receive one share of the Issuer's common stock at the time of vesting for no consideration.

2. The restricted stock units were granted under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan, as amended. The RSUs vest in three equal annual installments on July 28, 2027, July 28, 2028 and July 28, 2029, subject to the reporting person's continued service through each vesting date.

	/s/ Michael Abrams	11/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)